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Background: Hyperlipidemia is a common complication after kidney transplantation. However, there is little
long-term data on the efficacy and tolerability of statin therapy in kidney transplant recipients.
Methods: We performed a prospective 3-year study to investigate the effects of atorvastatin treatment in 15
hypercholesterolemic stable renal allograft recipients on maintenance immunosuppression with corticosteroid
and cyclosporine. Results were compared with data from 15 historical controls matched for baseline
hyperlipidemia and renal allograft function who had been treated with simvastatin.
Results: Patients in the two treatment groups showed similar baseline characteristics. The average dosages of
atorvastatin and simvastatin were 9.25  2.82 mg and 8.38  1.86 mg, respectively. Atorvastatin treatment
reduced total cholesterol (TC) by 31.1%, 27.7%, 25.9% and 28.9%, and low-density lipoprotein (LDL) by
43.4%, 37.4%, 36.8% and 41.6%, after 3, 12, 24 and 36 months of treatment, respectively. A significant reduction
in triglycerides (TG) was noted after 3 and 9 months, but was not sustained. High-density lipoprotein levels
were unaltered. Reductions in TC and LDL after simvastatin treatment appeared less pronounced, although the
differences did not reach statistical significance. At last follow-up, 90.9% of atorvastatin-treated patients achieved
target LDL of less than 3.4 mmol/L, compared with 78.6% of the simvastatin group. No patients developed
adverse reactions including abnormalities in liver enzyme or creatine kinase levels. Acute rejection was not
observed, although one patient on simvastatin developed chronic allograft nephropathy.
Conclusion: Atorvastatin and simvastatin demonstrated sustained efficacy in reducing the levels of TC and
LDL in stable renal allograft recipients. While atorvastatin may be more potent than simvastatin in the treatment
of hypercholesterolemia, its TG-lowering effect was not sustained with long-term treatment. The difference in
the therapeutic efficacy between the two drugs might have been due to dose rather than to the drugs themselves.
[Hong Kong J Nephrol 2006;8(1):17–23]
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INTRODUCTION
Vascular complications constitute the principal cause
of mortality after kidney transplantation, and
hyperlipidemia is an important and prevalent con-
tributory factor [1]. Immunosuppressive medications,
notably corticosteroids and calcineurin inhibitors,
exert adverse effects on the lipid profile [2]. These are
confounded by genetic predispositions and, in some
patients, suboptimal renal allograft function. It has been
reported that renal allograft recipients show increased
levels of total cholesterol (TC), low-density lipoprotein
(LDL), very low-density lipoprotein (VLDL) and
triglycerides (TG) [3–5]. Dietary intervention alone is
often inadequate to normalize the lipid profile [6,7],
and statin therapy is often required [8,9].
Despite the established efficacy of statins in the
treatment of hyperlipidemia in non-immunosuppressed
subjects, long-term data in renal allograft recipients
are relatively limited [10–12]. Confounding factors in
kidney transplant recipients include the effects of
concomitant medications on lipid metabolism and
changes in the dose of immunosuppressive agents with
time after transplantation, so that whether short-term
beneficial results are sustained with longer follow-up
remains to be established. Atorvastatin and simvastatin
are both commonly used in the treatment of hyper-
cholesterolemia, and the former has the additional effect
of reducing TG level. Previous short-term studies have
reported that simvastatin reduces TC and LDL levels
in renal allograft recipients by 20–25% and 29%,
respectively [13,14]. This study aimed to determine the
long-term outcome of atorvastatin therapy in hyper-
cholesterolemic Chinese renal allograft recipients with
stable allograft function, and to compare the results with
historical controls with comparable hyperlipidemia who
had been treated with simvastatin.
PATIENTS AND METHODS
Renal transplant patients under the care of the Queen
Mary Hospital Renal Unit who were receiving
maintenance immunosuppression with corticosteroid
and cyclosporine (with or without azathioprine), and
who had persistent hypercholesterolemia as defined
below were included in the study. Other inclusion
criteria included: age more than 16 years at the time
of transplant, post-transplant time of more than
6 months, and absence of acute rejection in the past 6
months. Patients who had been treated with rapamycin
were excluded. Patients with serum creatinine above
350 mol/L were excluded, and data were censored
when serum creatinine reached this level in patients
with deteriorating allograft function. Controls were
identified retrospectively. They included renal allograft
recipients at the same center who were matched on a
one-to-one basis with regard to gender, age (within 5
years) and the pattern and severity of hyperlipidemia
(difference < 10%), but who had been treated with
simvastatin.
Corticosteroid treatment was methylprednisolone 3
mg/kg/day intravenously for 3 days, followed by
prednisolone 30 mg/day tapered to 7.5 mg/day after 6
months. Cyclosporine A (Neoral®; Novartis, Basel,
Switzerland) was started at 0.8 mg/kg/day with target
12-hour trough levels of 250–300 g/L within the
first 3 months, 180–220  g/L after 6 months, and 100–
150 g/L after 1 year. Azathioprine was started at
2.5 mg/kg/day and tapered to 2 mg/kg/day after 6
months and 1.5 mg/kg/day after 1 year.
Hypercholesterolemia was defined as TC of at least
6.3 mmol/L or LDL of at least 4.2 mmol/L in fasting
lipid profiles repeated at least 3 months apart despite
dietary modifications [15]. Hypercholesterolemic
patients were treated with atorvastatin at a starting dose
of 10 mg daily. The following parameters were
documented at baseline and then every 3 months, for
a follow-up of 36 months: clinical symptoms and
signs; blood pressure; fasting lipid profile including
TC (upper limit of normal, ULN, 5.2 mmol/L), LDL
(ULN, 3.4 mmol/L), high-density lipoprotein (HDL)
(lower limit of normal, 1.0 mmol/L) and TG (ULN,
1.7 mmol/L); serum creatinine; 12-hour trough serum
cyclosporine; creatine phosphokinase (CPK); alanine
aminotransferase; alkaline phosphatase; and -glutamyl
transpeptidase. Patients were instructed to fast for at
least 8 hours before blood samples for lipid profile were
obtained. The dose of atorvastatin was titrated to
achieve LDL levels below 3.4 mmol/L. Statin treatment
was withdrawn in patients who developed abnormal
levels of liver enzymes or CPK.
Results from the atorvastatin-treated patients were
compared with those of hypercholesterolemic renal
allograft recipients from the same center, matched on
a one-to-one basis with regard to gender, age (within 5
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years) and the pattern and severity of hyperlipidemia
(difference < 10%), who had been treated with
simvastatin (i.e. historical controls).
Statistical analysis
Serial results were compared between patients treated
with atorvastatin and historical controls treated with
simvastatin. Data analyses were performed using SPSS
10.0 (SPSS Inc, Chicago, IL, USA). The chi-square
test, Student’s t test, Wilcoxon rank sum test and
Pearson’s correlation coefficient were used where
appropriate. Continuous variables are expressed as
mean  standard deviation unless otherwise stated. A
two-tailed p value of less than 0.05 was taken to indicate
statistical significance.
RESULTS
The study included 15 hypercholesterolemic patients
treated with atorvastatin and 15 simvastatin-treated
controls (Table 1). In addition to the characteristics
stipulated by matching criteria, the two groups showed
similar prevalence rates of diabetes mellitus and the
use of -blockers or diuretics. The causes of primary
renal diseases included: immunoglobulin A nephro-
pathy (n = 5), diabetic nephropathy (n = 2), lupus
nephritis (n = 1), other forms of chronic glomerulo-
nephritis (n = 19), adult polycystic kidney disease (n =
1), Alport’s syndrome (n = 1), and renal tuberculosis
(n = 1). The distribution of etiologies was similar in
the two groups.
Statin therapy was started at 56.6  31.9 months
and 45.8  31.2 months after transplantation in the
atorvastatin and simvastatin groups, respectively (p =
0.356). The starting dose of either statin was 10 mg
daily in all subjects. Apart from similar lipid profiles at
baseline (Table 1), the two groups also had similar daily
doses of prednisolone, cyclosporine concentration, and
serum creatinine levels at all study time points (data
not shown).
Treatment with atorvastatin resulted in significant
and sustained reductions in TC and LDL at all time
points compared with baseline (Table 2). After 3, 12,
24 and 36 months of treatment, TC and LDL were
reduced by 31.1%, 27.7%, 25.9% and 28.9%, and by
43.4%, 37.4%, 36.8% and 41.6%, respectively (Table
3). TG was significantly decreased after 3 and 9 months
(Table 2), but this decrease was not sustained. The level
of HDL was not altered in a consistent manner over
time. Simvastatin treatment resulted in significant
reductions in TC and LDL, but the HDL level remained
unaltered (Table 2). The reduction in TG barely reached
statistical significance after 24 months of simvastatin
treatment. The reductions in TC and LDL were more
pronounced after treatment with atorvastatin than with
simvastatin, although the differences between the two
groups did not achieve statistical significance at some
study time points (Table 3).
The target LDL level (< 3.4 mmol/L) was achieved
by 77.8%, 75.0%, 85.7%, 77.8%, 76.9% and 90.9% of
patients after treatment with atorvastatin for 3, 6, 9,
Table 1. Baseline characteristics of hyperlipidemic renal allograft recipients treated with either atorvastatin or simvastatin*
Atorvastatin (n = 15) Simvastatin (n = 15) p
Age at transplant (yr) 36.8  12.5 40.8  7.0a 0.302
Males 8 (53.3%) 5 (33.3%) 0.269
Median duration of dialysis (mo) 16.8 22.0 0.097
Cadaveric transplant 11 (73.3%) 13 (86.7%) 0.227
Follow-up after transplantation (mo) 56.6  31.9 45.8  31.2 0.356
Serum creatinine at baseline (mol/L) 142.93  53.36a 120.73  40.23a 0.209
Post-transplant diabetes mellitus 5 (33.3%) 2 (13.3%) 0.390
Hypertension 13 (86.7%) 13 (86.7%) 1.000
HBsAg positive 2 (13.3%)  1 (6.7%) 1.000
Anti-HCV positive 011 2 (13.3%) 0.483
Body weight (kg) 60.1  9.8a 57.7  10.0 0.502
Use of -blockers 10 (66.7%) 10 (66.7%) 1.000
Use of diuretics 4 (26.7%) 2 (13.3%) 0.651
Prednisolone dose (mg/day) 7.85  2.23 8.17  1.48 0.651
Cyclosporine dose (mg/kg/day) 3.17  1.41 3.26  0.50 0.813
12-hour trough serum cyclosporine (g/L) 149.6  45.3a 160.8  44.0 . 0.524
Total cholesterol (mmol/L) 6.97  0.72 7.25  0.91 0.366
Triglycerides (mmol/L) 1.89  0.79 2.01  0.97 0.696
Low-density lipoprotein (mmol/L) 4.74  0.72 4.63  0.86 0.703
High-density lipoprotein (mmol/L) 1.35  0.44 1.73  0.73 0.091
*Data presented as mean  standard deviation or n (%). HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus.
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12, 24 and 36 months, respectively, compared with
87.5%, 50.0%, 85.7%, 62.5%, 85.7% and 78.6% at the
corresponding time points in the simvastatin group. The
differences were not significant at all time points. The
average dosages of atorvastatin and simvastatin were
9.25  2.82 mg and 8.38  1.86 mg, respectively. No
significant correlation was demonstrated between body
weight or serum creatinine and TC or LDL values (data
not shown).
Both atorvastatin and simvastatin were well
tolerated despite long-term administration. No patients
developed adverse reactions or required discontinuation
of treatment. Cyclosporine and serum creatinine levels
were unaltered after the addition of statin in both groups
(data not shown). No patients developed acute rejection
during statin therapy, although one simvastatin-treated
patient developed chronic allograft nephropathy with
doubling of baseline creatinine during the third year.
Patients treated with atorvastatin or simvastatin had
similar levels of alanine aminotransferase (mean of all
time points, 15.8  4.8 vs. 22.0  16.2 U/L; p = 0.115)
and CPK (mean of all time points, 112.3  92.8 vs.
71.6  21.9 U/L; p = 0.527) at all study time points.
DISCUSSION
Hyperlipidemia is a common complication after kidney
transplantation [1–3,8,9]. The prevalence varies with
time after transplantation, and up to 38% of patients
could be affected within the first 6 months [16].
Commonly observed abnormal lipid profiles include
increased TC, LDL, VLDL and TG levels [5]. Immuno-
suppressive medications such as corticosteroids,
cyclosporine and rapamycin are the major factors
contributing to hyperlipidemia in kidney transplant
recipients [5]. The short-term efficacy of some HMG-
CoA reductase inhibitors or fibrates has been reported
in the treatment of hyperlipidemia after renal
transplantation [13,17,18]. In contrast, there is much
less data on the long-term results, especially regarding
whether the efficacy is sustained, and tolerability of
treatment.
Atorvastatin exhibits higher potency than other
HMG-CoA reductase inhibitors in lowering cholesterol
levels [19–21], and its action of lowering TG presents
an added advantage in patients with mixed hyper-
lipidemia [22]. The latter is especially pertinent in renal
transplant recipients since the combined use of statin,
fibrate and cyclosporine may predispose patients to side
effects such as rhabdomyolysis and abnormal liver
biochemistry. This TG reduction has been attributed to
reduced hepatocyte cholesterol concentration, increased
expression of hepatocyte LDL receptors that can bind
both VLDL and LDL remnants, and reduced assembly
of VLDL [22]. Treatment with atorvastatin has also beenTa
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associated with improved endothelial function [23].
Moreover, there are emerging data that statins have
immunomodulatory properties independent of their
lipid-lowering actions, including the reduction of T-cell
activation and inflammatory-cell recruitment into
atherosclerotic lesions, and inhibition of interferon-
–induced expression of major histocompatibility
complex II on antigen presenting cells [21]. Whether
these additional actions modulate long-term renal
allograft function or survival remains to be established.
An earlier 3-month study reported reductions of TC
and LDL by 30% and 42%, respectively, after treatment
with atorvastatin, while cerivastatin treatment resulted
in corresponding reductions of 32% and 38% [11].
Due to its frequent association with rhabdomyolysis,
cerivastatin is seldom used [24] and was withdrawn
from the market in 2001. Another study with follow-
up of 1 year compared several statins including
atorvastatin [12]. While the results hinted at greater
efficacy with atorvastatin, details concerning the study
protocol and statistics were not presented. The effect
of fluvastatin in renal transplant patients was investi-
gated in another long-term study that showed significant
reduction of cardiovascular endpoints and lipid
lowering [25].
In the present series, we chose to examine the long-
term results with two commonly prescribed statins,
namely simvastatin and atorvastatin. Our data showed
that both drugs were effective and well tolerated in
kidney transplant recipients. Notably, rhabdomyolysis
and deranged liver biochemistry were not observed. On
the whole, more than 75% of patients achieved target
lipid levels after treatment with atorvastatin or
simvastatin, and the results were maintained during
long-term follow-up. It is important that the treatment
efficacy is sustained, since our study included stable
patients who were subject to the lipogenic effects of
maintenance immunosuppressive medications on a
long-term basis. In this regard, the results showed that
the correction of hyperlipidemia by simvastatin and
atorvastatin was maintained throughout the 3 years of
follow-up. The magnitudes of reductions in TC and
LDL levels among our patients are similar to those of
other investigations in Caucasian subjects [19,26,27].
We noted lower TC and LDL levels with atorvastatin
than with simvastatin, although the differences did not
reach statistical significance at most study time points,
probably due to the small sample size.
The TG data are intriguing. The more prominent
TG-lowering effect of atorvastatin compared to other
statins is well established in non-transplant subjects.
Preliminary data from short-term studies also suggest
that atorvastatin is effective in lowering TG levels, but
long-term data are lacking [19,26]. Our results showed
that while the TG-lowering effect of atorvastatin may
be more pronounced than that of simvastatin within
the first year of treatment, it was unsustainable with
long-term therapy. Concomitant corticosteroid and
cyclosporine treatment might have contributed to
differences in the action of atorvastatin in kidney
transplant recipients and other subjects. Since LDL was
the primary treatment target in the present study, the
lack of sustained efficacy on TG might be related to
the dose used instead of the drug itself. These obser-
vations underscore the importance of further long-term
studies with more patients, in view of the emerging
association between hypertriglyceridemia and an
overall atherogenic lipid profile [3,28].
Our results did not show any significant effect of
atorvastatin or simvastatin on 12-hour cyclosporine
trough level and graft function. It is important to
note, however, that there is potentially a bilateral
pharmacokinetic interaction between atorvastatin and
cyclosporine, resulting in significantly increased HMG-
CoA reductase inhibitory activity in patients who are
taking atorvastatin and cyclosporine concomitantly
[29]. In addition to immunomodulatory and anti-
inflammatory actions, treatment with HMG-CoA
reductase inhibitors has been associated with reduced
levels of C-reactive protein and thrombogenicity [21,
23,30–32]. Furthermore, it has been demonstrated
that hyperlipidemia per se is a non-immunologic risk
Table 3. Percentage reduction of total cholesterol and low-density lipoprotein in atorvastatin- or simvastatin-treated renal allograft
recipients compared to baseline
Month 3 Month 6 Month 9 Month 12 Month 24 Month 36
Total cholesterol (mmol/L)
   Atorvastatin –31.1  9.5 –26.9  7.0 –30.8  7.5 –27.7  11.3 –25.9  12.5 –28.9  11.7
   Simvastatin   –25.6  11.7   –17.8  17.5 –31.5  5.9 –18.2  15.5 –24.2  14.0 –24.0  12.4
   p 0.300 0.317 0.870 0.164 0.734 0.319
Low-density lipoprotein (mmol/L)
   Atorvastatin   –43.4  11.4 –36.3  8.4   –43.3  10.7 –37.4  13.9 –36.8  17.6 –41.6  15.7
   Simvastatin   –30.3  14.0   –27.8  16.5   –35.4  15.8 –24.1  18.8 –34.7  16.9 –35.7  14.4
   p 0.050 0.360 0.300 0.114 0.761 0.378
K.C. Tse, et al
22 Hong Kong J Nephrol • April 2006 • Vol 8 • No 1
factor for the development of chronic allograft
nephropathy [33–35]. We, therefore, selected only
patients who were receiving the same immuno-
suppressive regimen, so obviating the confounding
effect of different immunosuppressive agents; but
whether statins or hyperlipidemia treatment altered the
incidence or course of chronic allograft nephropathy
requires further investigations.
Since the present study involved use of historical
controls, there is a potential difference in the target LDL
levels between the cases and controls. In order to
circumvent the problem, historical controls were chosen
so that the date of starting simvastatin was in the period
1994–2000, after the publication of the National
Cholesterol Education Program (NCEP) Panel II
recommendations in 1993. Thus, the target LDL level
for historical controls was likely to be similar to that
for the atorvastatin group, which had target LDL levels
based on the NCEP Panel III in 2001. In addition,
although a dietary history was lacking, all patients
had been advised to follow strict diet restrictions to
minimize the effects of differences in dietary intake.
Finally, while the lack of potential adverse effects of
both statins might have been due to the small sample
size, the safety profiles of both drugs are well
established.
In conclusion, both simvastatin and atorvastatin
demonstrated sustained efficacy in the treatment of
hypercholesterolemia in kidney transplant recipients
receiving maintenance immunosuppression with
prednisolone and cyclosporine. Atorvastatin appeared
to be more potent than simvastatin in reducing
LDL and TC. However, the TG-lowering effect of
atorvastatin may not be sustained with prolonged
therapy. The difference in the therapeutic efficacy
between the two drugs might have been due to dose
rather than to the drugs themselves. Both drugs are safe,
and there was no detrimental effect on graft function.
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